Literature DB >> 6778860

Isolation and characterization of human factor VII. Activation of factor VII by factor Xa.

S P Bajaj, S I Rapaport, S F Brown.   

Abstract

A procedure has been developed for the isolation of human Factor VII to apparent homogeneity as judged by the analytical disc electrophoretic system of Davis (pH 8.9) and by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The isolated procedure involves adsorption of Factor VII onto barium citrate, ammonium sulfate fractionation, DEAE-Sephadex chromatography, and preparative polyacrylamide gel electrophoresis. The overall yield of Factor VII is 15 to 20% of starting plasma and the purified protein has a specific activity of 1800 to 2200 units/mg in a clotting assay. Factor VII protein obtained by this method has only 1.3 to 1.5 times more activity in a one-stage clotting assay than in a coupled amidolytic assay (Seligsohn, U., Osterud, B., and Rapaport, S. I. (1978) Blood 52, 978-988), which is taken to mean than it contains less than 5% of activated Factor VII. Human Factor VII is a single chain glycoprotein with an apparent molecular weight of 50,000 +/- 2,000 as determined by SDS-polyacrylamide gel electrophoresis. It has alanine as an NH2-terminal amino acid residue and contains 8.8 gama-carboxyglutamic acid residues/mol of protein. Incubation of purified Factor VII with Factor Xa in the presence of Ca(II) and phospholipid results in a rapid up to 25-fold increase in its clotting activity. Factor VII activity in the coupled amidolytic assay remains unchanged throughout the incubation. Activation of Factor VII by Factor Xa is associated with cleavage of the Mr = 50,000 native protein to a protein consisting of two chains of Mr = about 26,000 and 22,000 as determined by SDS-polyacrylamide gel electrophoresis in the presence of 2-mercaptoethanol. Other properties of human Factor VII, including its amino acid composition and its reactions with an anti-Factor VII antibody, are described.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6778860

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

2.  Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms.

Authors:  Shiva Keshava; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  J Thromb Haemost       Date:  2020-06-25       Impact factor: 5.824

3.  Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII:Ag.

Authors:  T Takase; E G Tuddenham; S Chand; A H Goodall
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

4.  Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.

Authors:  T Takase; E G Tuddenham; S Chand; A H Goodall
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

5.  Intrinsic versus extrinsic coagulation. Kinetic considerations.

Authors:  B J Warn-Cramer; S P Bajaj
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

6.  Expression and purification of recombinant human coagulation factor VII fused to a histidine tag using Gateway technology.

Authors:  Raheleh Halabian; Mahdi Edalati Fathabad; Nasser Masroori; Amaneh Mohammadi Roushandeh; Sasan Saki; Nasser Amirizadeh; Ali Jahanian Najafabadi; Ahmad Gharehbaghian; Mehryar Habibi Roudkenar
Journal:  Blood Transfus       Date:  2009-10       Impact factor: 3.443

7.  Carbohydrates and activity of natural and recombinant tissue factor.

Authors:  Jolanta Krudysz-Amblo; Mark E Jennings; Kenneth G Mann; Saulius Butenas
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

8.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Binding of human factor VII and VIIa to monocytes.

Authors:  G J Broze
Journal:  J Clin Invest       Date:  1982-09       Impact factor: 14.808

10.  Human alveolar macrophages synthesize factor VII in vitro. Possible role in interstitial lung disease.

Authors:  H A Chapman; C L Allen; O L Stone; D S Fair
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.